Rua Life Sciences PLC (RUA) - Net Assets

Latest as of September 2025: GBX7.18 Million GBX ≈ $874.21 USD

Based on the latest financial reports, Rua Life Sciences PLC (RUA) has net assets worth GBX7.18 Million GBX (≈ $874.21 USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.12 Million ≈ $1.11K USD) and total liabilities (GBX1.93 Million ≈ $235.07 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Rua Life Sciences PLC (RUA) financial obligations for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX7.18 Million
% of Total Assets 78.81%
Annual Growth Rate 10.55%
5-Year Change -13.1%
10-Year Change 505.27%
Growth Volatility 306.84

Rua Life Sciences PLC - Net Assets Trend (1994–2025)

This chart illustrates how Rua Life Sciences PLC's net assets have evolved over time, based on quarterly financial data. Also explore how large is Rua Life Sciences PLC's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Rua Life Sciences PLC (1994–2025)

The table below shows the annual net assets of Rua Life Sciences PLC from 1994 to 2025. For live valuation and market cap data, see RUA stock market capitalisation.

Year Net Assets Change
2025-03-31 GBX7.39 Million
≈ $899.39		 +2.92%
2024-03-31 GBX7.18 Million
≈ $873.84		 +53.36%
2023-03-31 GBX4.68 Million
≈ $569.79		 -28.87%
2022-03-31 GBX6.58 Million
≈ $801.08		 -22.60%
2021-03-31 GBX8.51 Million
≈ $1.03K		 +273.89%
2020-03-31 GBX2.27 Million
≈ $276.80		 -24.17%
2019-03-31 GBX3.00 Million
≈ $365.01		 +195.28%
2018-03-31 GBX1.02 Million
≈ $123.62		 -3.41%
2017-03-31 GBX1.05 Million
≈ $127.99		 -13.87%
2016-03-31 GBX1.22 Million
≈ $148.59		 -24.34%
2015-03-31 GBX1.61 Million
≈ $196.39		 -2.20%
2014-03-31 GBX1.65 Million
≈ $200.81		 -39.00%
2013-03-31 GBX2.71 Million
≈ $329.20		 -14.86%
2012-03-31 GBX3.18 Million
≈ $386.67		 +1.79%
2011-03-31 GBX3.12 Million
≈ $379.86		 -42.32%
2010-03-31 GBX5.41 Million
≈ $658.61		 -11.73%
2009-03-31 GBX6.13 Million
≈ $746.09		 -13.80%
2008-03-31 GBX7.11 Million
≈ $865.57		 +140.26%
2007-03-31 GBX2.96 Million
≈ $360.27		 -42.03%
2006-03-31 GBX5.11 Million
≈ $621.50		 -9.64%
2005-03-31 GBX5.65 Million
≈ $687.81		 -25.29%
2004-03-31 GBX7.57 Million
≈ $920.69		 +9.54%
2003-03-31 GBX6.91 Million
≈ $840.50		 -85.05%
2002-03-31 GBX46.21 Million
≈ $5.62K		 +28.49%
2001-03-31 GBX35.96 Million
≈ $4.38K		 -13.45%
2000-03-31 GBX41.55 Million
≈ $5.06K		 +911.24%
1999-03-31 GBX4.11 Million
≈ $499.95		 +62.86%
1998-03-31 GBX2.52 Million
≈ $306.98		 -19.08%
1997-03-31 GBX3.12 Million
≈ $379.37		 +359.88%
1996-03-31 GBX678.00K
≈ $82.49		 +1440.91%
1995-03-31 GBX44.00K
≈ $5.35		 -86.67%
1994-03-31 GBX330.00K
≈ $40.15		 --

Equity Component Analysis

This analysis shows how different components contribute to Rua Life Sciences PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6154.2% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Common Stock GBX3.10 Million 42.52%
Other Comprehensive Income GBX10.46 Million 143.40%
Other Components GBX13.71 Million 187.85%
Total Equity GBX7.30 Million 100.00%

Rua Life Sciences PLC Competitors by Market Cap

The table below lists competitors of Rua Life Sciences PLC ranked by their market capitalization.

Company Market Cap
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
 $147.39K
Vergnet
PA:ALVER
 $147.53K
Portmeirion Group PLC
LSE:PMP
 $149.71K
Lipigon Pharmaceuticals AB
ST:LPGO
 $149.98K
Fulcrum Metals PLC
LSE:FMET
 $147.22K
Metrics in Balance NV
PA:MLMIB
 $144.89K
Tasty Plc
LSE:TAST
 $144.44K
IQ-AI LTD. LS -01
F:5Y1
 $144.21K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Rua Life Sciences PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 7,182,000 to 7,298,000, a change of 116,000 (1.6%).
  • Net income of 1,000 contributed positively to equity growth.
  • Other comprehensive income increased equity by 110,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX1.00K +0.01%
Other Comprehensive Income GBX110.00K +1.51%
Other Changes GBX5.00K +0.07%
Total Change GBX- 1.62%

Book Value vs Market Value Analysis

This analysis compares Rua Life Sciences PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 165.82x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 84.49x to 165.82x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-03-31 GBX0.23 GBX19.50 x
1995-03-31 GBX0.03 GBX19.50 x
1996-03-31 GBX0.47 GBX19.50 x
1997-03-31 GBX2.13 GBX19.50 x
1998-03-31 GBX1.40 GBX19.50 x
1999-03-31 GBX1.99 GBX19.50 x
2000-03-31 GBX17.44 GBX19.50 x
2001-03-31 GBX11.51 GBX19.50 x
2002-03-31 GBX12.38 GBX19.50 x
2003-03-31 GBX1.80 GBX19.50 x
2004-03-31 GBX1.98 GBX19.50 x
2005-03-31 GBX1.48 GBX19.50 x
2006-03-31 GBX1.33 GBX19.50 x
2007-03-31 GBX0.77 GBX19.50 x
2008-03-31 GBX1.58 GBX19.50 x
2009-03-31 GBX1.26 GBX19.50 x
2010-03-31 GBX1.11 GBX19.50 x
2011-03-31 GBX0.64 GBX19.50 x
2012-03-31 GBX0.65 GBX19.50 x
2013-03-31 GBX0.56 GBX19.50 x
2014-03-31 GBX0.34 GBX19.50 x
2015-03-31 GBX0.33 GBX19.50 x
2016-03-31 GBX0.24 GBX19.50 x
2017-03-31 GBX0.19 GBX19.50 x
2018-03-31 GBX0.18 GBX19.50 x
2019-03-31 GBX0.23 GBX19.50 x
2020-03-31 GBX0.15 GBX19.50 x
2021-03-31 GBX0.48 GBX19.50 x
2022-03-31 GBX0.30 GBX19.50 x
2023-03-31 GBX0.21 GBX19.50 x
2024-03-31 GBX0.21 GBX19.50 x
2025-03-31 GBX0.12 GBX19.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Rua Life Sciences PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.01%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.02%
  • • Asset Turnover: 0.44x
  • • Equity Multiplier: 1.27x
  • Recent ROE (0.01%) is above the historical average (-57.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 105.45% 36.02% 0.46x 6.30x GBX315.00K
1995 -647.73% -29.75% 0.49x 44.18x GBX-289.40K
1996 -53.39% -20.70% 0.85x 3.04x GBX-429.80K
1997 -36.34% -52.14% 0.47x 1.50x GBX-1.44 Million
1998 -23.54% -32.98% 0.46x 1.55x GBX-846.30K
1999 -24.36% -36.02% 0.51x 1.32x GBX-1.41 Million
2000 -4.25% -51.10% 0.08x 1.07x GBX-5.92 Million
2001 -17.31% -168.20% 0.10x 1.07x GBX-9.82 Million
2002 -27.88% -278.45% 0.09x 1.06x GBX-17.50 Million
2003 -569.75% -2854.10% 0.15x 1.34x GBX-40.05 Million
2004 6.98% 146.67% 0.04x 1.06x GBX-228.70K
2005 -33.03% -1362.77% 0.02x 1.06x GBX-2.43 Million
2006 -10.24% -36.70% 0.25x 1.13x GBX-1.03 Million
2007 -71.63% -768.48% 0.08x 1.24x GBX-2.42 Million
2008 -16.29% -78.10% 0.19x 1.10x GBX-1.87 Million
2009 -20.37% -99.21% 0.19x 1.10x GBX-1.86 Million
2010 -35.53% -141.19% 0.23x 1.12x GBX-2.46 Million
2011 -80.11% -159.30% 0.42x 1.21x GBX-2.81 Million
2012 1.12% 1.13% 0.88x 1.12x GBX-282.20K
2013 -20.60% -22.32% 0.82x 1.13x GBX-828.03K
2014 -29.92% -196.42% 0.13x 1.18x GBX-658.80K
2015 -13.59% -38.04% 0.32x 1.10x GBX-380.84K
2016 -34.34% -67.04% 0.47x 1.09x GBX-541.48K
2017 -17.98% -38.60% 0.43x 1.08x GBX-294.34K
2018 -3.35% -8.42% 0.37x 1.07x GBX-135.60K
2019 -20.30% -131.53% 0.15x 1.03x GBX-909.00K
2020 -35.87% -166.87% 0.20x 1.10x GBX-1.04 Million
2021 -17.06% -94.96% 0.15x 1.19x GBX-2.30 Million
2022 -31.39% -127.20% 0.21x 1.16x GBX-2.73 Million
2023 -42.77% -91.92% 0.38x 1.21x GBX-2.47 Million
2024 -20.05% -65.72% 0.27x 1.14x GBX-2.16 Million
2025 0.01% 0.02% 0.44x 1.27x GBX-728.80K

Industry Comparison

This section compares Rua Life Sciences PLC's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $46,444,119
  • Average return on equity (ROE) among peers: -19.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Rua Life Sciences PLC (RUA) GBX7.18 Million 105.45% 0.27x $147.24K
AOTI Inc (AOTI) $3.41 Million 51.02% 1.74x $891.93K
Creo Medical Group PLC (CREO) $1.37 Million -123.43% 0.18x $633.60K
EKF Diagnostics Holdings Plc (EKF) $-3.03 Million 0.00% 0.00x $1.39 Million
Inspiration Healthcare Group PLC (IHC) $1.65 Million 0.00% 0.38x $322.92K
NIOX Group PLC (NIOX) $81.90 Million 19.66% 0.20x $3.41 Million
Polarean Imaging Plc (POLX) $8.73 Million -75.05% 0.25x $11.75K
Smith & Nephew PLC (SN) $273.58 Million 25.01% 1.35x $118.48 Million
Surgical Innovations Group plc (SUN) $3.93 Million -51.73% 0.98x $51.07K

About Rua Life Sciences PLC

LSE:RUA UK Medical Devices
Market Cap
$147.24K
GBX1.21 Billion GBX
Market Cap Rank
#30891 Global
#1055 in UK
Share Price
GBX19.50
Change (1 day)
-4.88%
52-Week Range
GBX10.50 - GBX20.50
All Time High
GBX176.50
Categories
Companies in UK Medical Devices
About

RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast… Read more